MAC-8001 / DaCure Therapeutics - LARVOL DELTA

MAC-8001: A KRAS-targeting molecular glue-antibody conjugate with robust antitumor activity in KRAS-mutant cancers (AACR 2026) - "The modular design of this MAC platform allows straightforward adaptation to other tumor-associated antigens,such as TROP2, thereby broadening its translational potential across RAS-driven malignancies. Collectively, these findings establish a novel therapeutic paradigm that may overcome the inherent limitations of systemic KRAS modulation."

Oncology • Pancreatic Ductal Adenocarcinoma • BRAF • CD276 • KRAS